Jun 08, 2021 / 12:50PM GMT
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD
Great. Well, great. Good morning, everybody. Thanks for joining us. I'm Terence Flynn, the biopharma analyst at Goldman Sachs. And we're very pleased to have Johnson & Johnson with us. Joining us from the company this morning is Mathai Mammen, who is Global Head of R&D. Mathai, thank you so much for joining us. I really appreciate your time today.
Mathai Mammen - Johnson & Johnson - Global Head of Research & Development of Janssen Pharmaceutical
It's my great pleasure, Terence. Happy to be here.
Questions and Answers:
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MDGreat. Maybe just to start a couple of high-level questions. The first one I had is just as you think about your capabilities on the R&D side, what do you think really differentiates J&J's approach? And again, as we think about kind of the implications of COVID, any changes to R&D that you're making as a result coming out of the
Trustpilot
